ReviewDrugs1991
A review of the pharmacokinetics of cefpodoxime proxetil.
Review in Drugs, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 90 citations in OpenAlex.
- Impact of cefpodoxime proxetil and amoxicillin on the normal oral and intestinal microflora.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1993Trial
- Appropriateness and Abuse of Antipyretics, Anti-Inflammatory Drugs and Antibiotics in Children and Adults.Antibiotics (Basel, Switzerland) · 2026Review
- Elucidating the mechanism of cefpodoxime-BSA interaction via a combination of multi-spectroscopic methods and molecular docking simulations.Scientific reports · 2026Article
- [Oral antibiotics: even in severe infections?]Innere Medizin (Heidelberg, Germany) · 2026Review
- Article
- Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults.Cell reports · 2022Article
- FDA-Approved Oximes and Their Significance in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282.ACS infectious diseases · 2020Article
- Role of cephalosporins in the era of Clostridium difficile infection.The Journal of antimicrobial chemotherapy · 2017Review
- Formulation and in vitro characterization of cefpodoxime proxetil gastroretentive microballoons.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2011Article
- Cefpodoxime: pharmacokinetics and therapeutic uses.Indian journal of pediatrics · 2003Article
- Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.Paediatric drugs · 2001Review
- Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.Antimicrobial agents and chemotherapy · 1996Article
- Pharmacokinetics of anti-infective agents in paediatric patients.Clinical pharmacokinetics · 1994Review
- Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.Antimicrobial agents and chemotherapy · 1993Article
- Cefetamet pivoxil clinical pharmacokinetics.Clinical pharmacokinetics · 1993Review
- Review
- Microbiological conclusions.Drugs · 1991Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefpodoxime proxetil is an orally absorbed broad spectrum third generation cephalosporin antibacterial. It is a prodrug that is de-esterified in vivo to its active metabolite, cefpodoxime. After single- and multiple-dose (12-hourly) administration of cefpodoxime proxetil in the therapeutic dose range of 100 to 400mg of cefpodoxime equivalents, average peak plasma concentrations of cefpodoxime range from 1.0 to 4.5 mg/L and occur between 1.9 and 3.1 hours after administration. The half-life of cefpodoxime ranges from 1.9 to 2.8 hours. The absolute bio-availability of cefpodoxime proxetil tablets is 50%, and absorption is enhanced by concomitant administration of food. Raising gastric pH by pretreatment with antacids or H2-receptor antagonists results in reduced absorption. Binding of cefpodoxime to human plasma or serum protein is low (18 to 23%), suggesting that cefpodoxime should readily transfer across the capillary lining into tissues. Cefpodoxime undergoes minimal metabolism in humans. Drug not absorbed is degraded in the gastrointestinal tract and excreted in the faeces. As expected for a drug eliminated primarily by renal excretion, the disposition of cefpodoxime is altered in patients with impaired renal function; the half-life increases, while apparent plasma clearance and renal clearance decrease. The pharmacokinetics of cefpodoxime after oral administration of cefpodoxime proxetil are not affected by age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.